Gemini Therapeutics, Inc. (GMTX)
| Market Cap | 74.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -68.05M |
| Shares Out | 43.23M |
| EPS (ttm) | -1.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 101,050 |
| Open | 1.71 |
| Previous Close | 1.68 |
| Day's Range | 1.60 - 1.79 |
| 52-Week Range | 1.16 - 6.61 |
| Beta | n/a |
| Analysts | Sell |
| Price Target | 1.91 (+10.4%) |
| Earnings Date | Aug 11, 2022 |
About GMTX
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for GMTX stock is "Sell." The 12-month stock price forecast is 1.91, which is an increase of 10.40% from the latest price.
News
Gemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Gemini Therapeutics, Inc. (GMTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...
Gemini Therapeutics Reports 2021 Financial Results
Remote-First-Company/Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021. “As previously announced this year, Gemini Th...
Read Why Did Jefferies Downgrade Gemini Therapeutics To Hold
Jefferies has cut Gemini Therapeutics Inc (NASDAQ: GMTX) to Hold as the Company explores alternatives. The analyst Chris Howerton has also reduced the price target to $1.50, down from $23 after the Comp...
Gemini Therapeutics Provides Corporate Update
Remote-First-Company/Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related ma...
Gemini Therapeutics Provides GEM103 Program Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular dege...
Gemini Therapeutics Shares Jump As HC Wainwright Sees Over 500% Upside
H.C. Wainwright initiated coverage of Gemini Therapeutics Inc (NASDAQ: GMTX) with a Buy rating and $20 price target. In the near term, the expected Phase 2a readout for lead asset GEM103 can serve as a...
Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular dege...
Gemini Therapeutics Announces Poster Presentation at AAO 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular dege...
Gemini Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...
Should You Buy Gemini Therapeutics (GMTX) Ahead of Earnings?
Gemini Therapeutics (GMTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular dege...
Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular dege...
Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geo...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular dege...
Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement The...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at E...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...
Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...
Is the Options Market Predicting a Spike in Gemini Therapeutics (GMTX) Stock?
Investors need to pay close attention to Gemini Therapeutics (GMTX) stock based on the movements in the options market lately.
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at C...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...
Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular dege...
Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...
Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atro...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degen...
3 Biotech Stocks With Big Catalysts in June
Important events on the horizon could push these biotech stocks higher or press them further into the dirt.
Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular dege...
Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular dege...
Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatm...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular dege...